ETRAFON 2-25 Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Etrafon 2-25, and when can generic versions of Etrafon 2-25 launch?
Etrafon 2-25 is a drug marketed by Schering and is included in one NDA.
The generic ingredient in ETRAFON 2-25 is amitriptyline hydrochloride; perphenazine. There are thirteen drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the amitriptyline hydrochloride; perphenazine profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ETRAFON 2-25?
- What are the global sales for ETRAFON 2-25?
- What is Average Wholesale Price for ETRAFON 2-25?
Summary for ETRAFON 2-25
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 1 |
| Patent Applications: | 26 |
| DailyMed Link: | ETRAFON 2-25 at DailyMed |
US Patents and Regulatory Information for ETRAFON 2-25
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Schering | ETRAFON 2-25 | amitriptyline hydrochloride; perphenazine | TABLET;ORAL | 014713-004 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for ETRAFON 2-25
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Schering | ETRAFON 2-25 | amitriptyline hydrochloride; perphenazine | TABLET;ORAL | 014713-004 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
